title: Letter by Bouatou et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
authors.affiliation: From Geneva University Hospitals, Division of Clinical Pharmacology and Toxicology, Switzerland.
authors.forename: Yassine
authors.initials: Y
authors.lastname: Bouatou
authors.affiliation: From Geneva University Hospitals, Division of Clinical Pharmacology and Toxicology, Switzerland.
authors.forename: Myriam
authors.initials: M
authors.lastname: El Biali
authors.affiliation: From Geneva University Hospitals, Division of Clinical Pharmacology and Toxicology, Switzerland.
authors.forename: Caroline Flora
authors.initials: CF
authors.lastname: Samer
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D019338:Polypharmacy; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D014859:Warfarin; D000069552:Rivaroxaban